MTAP is adjacent to the CDKN2A tumor suppressor and is often deleted in cancer
A genetic screen reveals genes that show synthetic lethality with MTAP deletion
Metabolite accumulation in MTAP-null cancers creates sensitivity to PRMT5 targeting
This vulnerability extends to the upstream and downstream enzymes, MAT2A and RIOK1